Xencor IncXNCREarnings & Financial Report
Xencor Inc is a clinical-stage biopharmaceutical company focused on developing engineered antibody and protein therapeutics using its proprietary technology platform. Its pipeline targets oncology, autoimmune disorders, and inflammatory diseases, and it collaborates with global pharmaceutical partners to advance candidates addressing unmet medical needs across major markets.
XNCR Q4 FY2025 Key Financial Metrics
Revenue
$28.2M
Gross Profit
N/A
Operating Profit
$-53.6M
Net Profit
$-6.7M
Gross Margin
N/A
Operating Margin
-189.9%
Net Margin
-23.6%
YoY Growth
-46.5%
EPS
$-0.09
Xencor Inc Q4 FY2025 Financial Summary
Xencor Inc reported revenue of $28.2M (down 46.5% YoY) for Q4 FY2025, with a net profit of $-6.7M (up 85.4% YoY) (-23.6% margin).
Key Financial Metrics
| Total Revenue | $28.2M |
|---|---|
| Net Profit | $-6.7M |
| Gross Margin | N/A |
| Operating Margin | -189.9% |
| Report Period | Q4 FY2025 |
Xencor Inc Annual Revenue by Year
Xencor Inc annual revenue history includes year-by-year totals (for example, 2025 revenue was $125.6M).
Xencor Inc Quarterly Revenue & Net Profit History
Xencor Inc results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2025 | $28.2M | -46.5% | $-6.7M | -23.6% |
| Q3 FY2025 | $21.0M | +18.0% | $-6.0M | -28.7% |
| Q2 FY2025 | $43.6M | +82.4% | $-30.8M | -70.7% |
| Q1 FY2025 | $32.7M | +104.6% | $-48.4M | -147.9% |
| Q4 FY2024 | $52.8M | +3.6% | $-45.6M | -86.3% |
| Q3 FY2024 | $17.8M | -69.9% | $-46.3M | -260.1% |
| Q2 FY2024 | $23.9M | -47.5% | $-67.3M | -281.7% |
| Q1 FY2024 | $16.0M | -15.6% | $-73.4M | -459.1% |
Income Statement
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $16.0M | $23.9M | $17.8M | $52.8M | $32.7M | $43.6M | $21.0M | $28.2M |
| YoY Growth | -15.6% | -47.5% | -69.9% | 3.6% | 104.6% | 82.4% | 18.0% | -46.5% |
Balance Sheet
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $896.9M | $840.6M | $999.9M | $951.9M | $904.7M | $879.4M | $868.8M | $875.5M |
| Liabilities | $297.1M | $291.9M | $294.0M | $277.9M | $264.8M | $259.1M | $243.5M | $239.9M |
| Equity | $600.1M | $550.5M | $708.9M | $677.6M | $639.9M | $620.4M | $625.3M | $635.6M |
Cash Flow
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-56.9M | $-67.3M | $-28.1M | $-49.8M | $-16.2M | $-36.4M | $-30.8M | $-51.7M |